These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20838204)

  • 1. Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy.
    Rublee DA; Chen SY; Mardekian J; Wu N; Rao P; Boulanger L
    Am J Ther; 2012 Jan; 19(1):24-32. PubMed ID: 20838204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
    Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated.
    Jacobson TA; Wertz DA; Hoy T; Kuznik A; Grochulski D; Cziraky M
    Mayo Clin Proc; 2008 Dec; 83(12):1316-25. PubMed ID: 19046550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in hypertensive patients without prior cardiovascular disease.
    Foody JM; Joyce AT; Jeffers BW; Liu LZ; Benner JS
    Am J Ther; 2011; 18(2):110-6. PubMed ID: 20216383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
    Hussein MA; Chapman RH; Benner JS; Tang SS; Solomon HA; Joyce A; Foody JM
    Am J Cardiovasc Drugs; 2010; 10(3):193-202. PubMed ID: 20387911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between statins on clinical endpoints: a population-based cohort study.
    Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
    Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
    Corrao G; Conti V; Merlino L; Catapano AL; Mancia G
    Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin.
    Jacobson TA; Wertz DA; Kuznik A; Cziraky M
    Curr Med Res Opin; 2013 Jul; 29(7):773-81. PubMed ID: 23647370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Statin Adherence on Cardiovascular Morbidity and All-Cause Mortality in the Primary Prevention of Cardiovascular Disease: A Population-Based Cohort Study in Finland.
    Rannanheimo PK; Tiittanen P; Hartikainen J; Helin-Salmivaara A; Huupponen R; Vahtera J; Korhonen MJ
    Value Health; 2015 Sep; 18(6):896-905. PubMed ID: 26409618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
    Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E
    Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice.
    Motsko SP; Russmann S; Ming EE; Singh VP; Vendiola RM; Jones JK
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1214-22. PubMed ID: 19780020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.